Amneal Pharmaceuticals, Inc. (AMRX) Financial Statements (2024 and earlier)

Company Profile

Business Address
,
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments26248341151213 
Cash and cash equivalents26248341151213 
Restricted cash and investments99625 
Receivables775707669636529 
Inventory, net of allowances, customer advances and progress billings531489491381457 
Inventory531489491381457 
Prepaid expense4241343538 
Contract with customer, asset, after allowance for credit loss21212
Other undisclosed current assets27258441 
Total current assets:1,4121,5201,5521,2101,287 
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization  645961
Operating lease, right-of-use asset56605970
Property, plant and equipment470514478478544 
Intangible assets, net (including goodwill)1,6951,7601,8271,8022,081 
Goodwill599593523420426 
Intangible assets, net (excluding goodwill)1,0961,1671,3051,3831,655 
Other noncurrent assets10321324468 
Other undisclosed noncurrent assets63   373 
Total noncurrent assets:2,3882,4202,4542,4563,066 
TOTAL ASSETS:3,7993,9404,0063,6664,353 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 538583614507514 
Taxes payable369  
Employee-related liabilities62593677 
Accounts payable 166131153103115 
Accrued liabilities 13172807766 
Other undisclosed accounts payable and accrued liabilities 241316316283257 
Debt3031442121 
Estimated litigation liability107     
Due to related parties2488618 
Other undisclosed current liabilities751511150 
Total current liabilities:753677677550554 
Noncurrent Liabilities
Long-term debt and lease obligation2,5922,6802,7352,6092,670 
Long-term debt, excluding current maturities2,5922,6802,7352,6092,631 
Capital lease obligations39 
Liabilities, other than long-term debt14787864039 
Deferred compensation liability, classified      
Estimated litigation liability49     
Due to related parties1048    
Other liabilities 8739864039 
Other undisclosed noncurrent liabilities99112151120194 
Total noncurrent liabilities:2,8382,8792,9722,7692,903 
Total liabilities:3,5903,5563,6493,3193,456 
Temporary equity, carrying amount251712   
Equity
Equity, attributable to parent, including:298360303232505 
Common stock      0
Additional paid in capital692658628607530 
Accumulated other comprehensive income (loss)10(25)(41)(0)(8) 
Accumulated deficit(406)(276)(287)(378)(21) 
Receivable from shareholders or affiliates for issuance of capital stock      (0)
Other undisclosed equity, attributable to parent33333 
Equity, attributable to noncontrolling interest(114)742115392 
Total equity:184367345347896 
TOTAL LIABILITIES AND EQUITY:3,7993,9404,0063,6664,353 

Income Statement (P&L) ($ in millions)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2,2122,0941,9931,6261,663 
Cost of revenue
(Cost of Goods and Services Sold)
(1,416)(1,302)(1,330)(1,147)(947) 
Other undisclosed gross profit (11)(23)(35)(126)  
Gross profit:785769628353716 
Operating expenses(884)(603)(537)(602)(533) 
Other operating income, net4     
Other undisclosed operating income (loss)0(14)  (203) 
Operating income (loss):(95)15391(249)(20) 
Nonoperating income (expense)(153)(121)(127)28(183) 
Investment income, nonoperating   07(3) 
Gain (loss), foreign currency transaction, before tax(12)(0)16(5)(20) 
Interest and debt expense(5)(5)(9)(6)(6) 
Income (loss) from continuing operations before equity method investments, income taxes:(253)27(44)(227)(209) 
Other undisclosed income from continuing operations before income taxes55966 
Income (loss) from continuing operations before income taxes:(248)31(36)(220)(203) 
Income tax expense (benefit)(7)(11)104(383)1 
Income (loss) from continuing operations:(255)2069(604)(201) 
Income (loss) before gain (loss) on sale of properties:2069(604)(201) 
Other undisclosed net income  5    
Net income (loss):(255)2069(604)(201) 
Net income (loss) attributable to noncontrolling interest125(10)2224233 
Other undisclosed net income (loss) attributable to parent(141)3  149 
Net income (loss) attributable to parent:(271)1391(362)(20) 
Preferred stock dividends and other adjustments (0)   (1) 
Other undisclosed net income (loss) available to common stockholders, basic141(3)    
Net income (loss) available to common stockholders, diluted:(130)1191(362)(21) 

Comprehensive Income ($ in millions)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(255)2069(604)(201) 
Comprehensive income (loss):(255)2069(604)(201) 
Comprehensive income (loss), net of tax, attributable to noncontrolling interest90(27)6523236 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7034(84)19142 
Comprehensive income (loss), net of tax, attributable to parent:(95)2750(353)(23) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: